Clinical Trial Search

Primary: Chronic Effectiveness (Through 6 Months) of the Freezor Xtra Catheter for the Treatment of AVNRT Using an Endocardial Approach. — 368; 29 Participants — p=<0.0001

Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001

Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants

Primary: Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting. — 324 Participants

Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events

Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants

Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants

Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG

Primary: Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events — 71; 14; 85; 83 Participants

Primary: The Percentage of Chronic Success of the NAVISTAR THERMOCOOL Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (PAF) — 66; 16 Percentage of…

Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants

Primary: Number of Patients With Reduction ≥ 15% in Left Ventricular End-systolic Volume (LVESV) — 5; 6 Participants — p=1.00

Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants

Primary: Primary Safety: Incidence of Composite, Serious Adverse Events Within 7 Days Post-Procedure — 5 participants

Primary: The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation. — 13.3 percentage of mortality

Primary: Atrial Tachyarrhythmia Recurrence in Participants — 37 participants

Primary: Number of Ventricular Ectopic Beats Recorded During Exercise (and Recovery) — 46; 0 number of ventricular beats

Primary: All Hospital Episodes (Emergency Room or Patient Request for OPD) Related to Treatment for Atrial Arrhythmia — 19; 76; 23 Participants — p=<0.0001

Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants

Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV

Primary: Percentage of Participants Free From VT at 1 Year Post-Treatment — 62 percentage of participants free from VT

Primary: Primary Safety:Incidence of Composite, Serious Adverse Events Within 7 Days Post Procedure — 3 participants

Primary: Percentage of Subjects With Complete Bidirectional Conduction Block. — 93.3 percentage of participants — p=.05

Primary: Rate of Subjects With a Device and/or Procedure-related SAE. — 7 Participants

Primary: Inhibition of Idiopathic Ventricular Tachycardia

Primary: Percent of Patients Reaching Target HR<100bpm Within 30 Minutes — 46.4; 95.8 percentage of participants — p=.0001

Primary: Atrial Ventricular Pacing Synchrony Success During Rest — 0; 38; 0; 2 Participants — p=<0.001

Primary: Atrial Fibrillation Burden — 2; 8.5 Percent time spent in atrial fibrillatio

Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants

Primary: The Incidence of Early Onset Primary Adverse Events — 5.5 percentage of participants